GlassScriptPhysician profile
Ted M Faro
NPI 1184621294
$7,552.88
in general payments reported to CMS, 2019-2025
42 companies · $901 in 2025
The $901 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $851 · 2021: $1,348 · 2022: $1,528 · 2023: $1,532 · 2024: $887 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,570.26 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $805.96 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $582.83 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $534.56 | 2019-2025 | |
| Amgen INC. | $409.08 | 2019-2025 | Repatha, Otezla, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $345.47 | 2019-2024 | Trintellix |
| Dexcom, INC. | $344.96 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $339.28 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $269.80 | 2019-2025 | Spravato |
| Merck Sharp & Dohme LLC | $269.03 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $253.64 | 2019-2025 | Rexulti |
| Allergan, INC. | $211.37 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $170.51 | 2019-2022 | |
| Astellas Pharma US INC | $159.94 | 2019-2024 | Veozah |
| Abbott Laboratories | $146.93 | 2021-2023 | Freestyle Libre 3 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Faro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.